The do's and don'ts for drug makers under EMA trial data publication policy

As the European Medicines Agency prepares to implement its policy on the proactive publication of clinical trial data, it is bracing itself for the inevitable disputes with pharmaceutical companies on what constitutes commercially confidential information in a clinical study report and should, therefore, not be made public.